Ibuprofene B. Braun (Ibuprofen)

Ibuprofen in Ibuprofene B. Braun non‑selectively inhibits the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are key in converting arachidonic acid to prostaglandins. By lowering prostaglandin levels, the drug reduces peripheral sensitisation of pain receptors, lowers the hypothalamic set‑point for temperature, and diminishes inflammatory exudate formation.

The appropriate dose of Ibuprofene B. Braun is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other individual factors. Healthcare professionals should follow local prescribing guidelines and adjust the dose as needed for each patient.

Safety data for intravenous ibuprofen in pregnancy are limited, and the product is classified as having an unknown pregnancy category. Caution is advised, and the drug should only be used if the potential benefit justifies the potential risk. Breastfeeding mothers should consult a healthcare professional before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Compared with oral ibuprofen, the intravenous form provides faster onset of analgesia and antipyresis, which is advantageous in acute care settings. Relative to ketorolac, ibuprofen has a similar efficacy profile but a slightly lower risk of renal adverse effects at equivalent doses, though both require careful monitoring in patients with renal impairment.

Ibuprofene B. Braun must be stored in a refrigerated environment at 2 °C to 8 °C. The solution should be kept in its original container, protected from light, and must not be frozen or shaken. Before administration, inspect the vial for particulate matter and ensure the solution is at room temperature if required by the infusion protocol.

The product is given by intravenous infusion. It may be administered undiluted or diluted in compatible IV fluids according to the prescribing information. The infusion rate is typically controlled to achieve the desired therapeutic effect while monitoring the patient for any adverse reactions, especially during the initial minutes of administration.

Serious risks include gastrointestinal bleeding or ulcer perforation, severe allergic reactions such as anaphylaxis, acute renal failure, hepatotoxicity, and platelet dysfunction leading to bleeding complications. Patients with a history of peptic ulcer disease, bleeding disorders, severe renal or hepatic impairment, or known hypersensitivity to NSAIDs should be monitored closely.

Ibuprofene B. Braun is contraindicated in patients with known hypersensitivity to ibuprofen or any other NSAIDs, active gastrointestinal bleeding or ulceration, severe uncontrolled heart failure, and in those with severe renal or hepatic impairment where the risk outweighs benefit. Caution is also advised for patients with asthma that is triggered by NSAIDs.